# A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients

> **NCT04056442** · PHASE2 · COMPLETED · sponsor: **Stero Biotechs Ltd.** · enrollment: 15 (actual)

## Conditions studied

- Steroid Dependent Crohn's Disease

## Interventions

- **DRUG:** Cannabidiol , synthetic form
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04056442
- **Lead sponsor:** Stero Biotechs Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-07
- **Primary completion:** 2022-11-07
- **Final completion:** 2022-11-07
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04056442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04056442, "A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04056442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*